In vivo pretargeting stands as a promising approach to harnessing the exquisite tumor-targeting properties of antibodies for nuclear imaging and therapy while simultaneously skirting their ...

We developed a new C-X-C chemokine receptor 4 (CXCR4)–targeting radiolabeled peptide, [68Ga]Ga/[177Lu]Lu-BL34, using a novel and potent cyclic peptide based on structure–activity relationship studies ...

The diagnosis and surveillance of clear cell renal cell carcinoma (ccRCC) remains a clinical challenge. The high and specific expression of the cluster of differentiation 70 (CD70) in ccRCC makes it a ...

Journal of Nuclear Medicine April 2026, jnumed.125.270997; DOI: https://doi.org/10.2967/jnumed.125.270997 ...

Imaging plays a critical role in the management of pheochromocytomas and paragangliomas and often guides treatment. The discovery of susceptibility genes associated with these tumors has led to better ...

Journal of Nuclear Medicine January 2026, jnumed.125.269933; DOI: https://doi.org/10.2967/jnumed.125.269933 ...

Bone mineral density (BMD) measurement by dual-energy x-ray absorptiometry (DXA) is an internationally accepted standard-of-care screening tool used to assess fragility-fracture risk. Society ...

PET is a powerful molecular imaging technique that can provide functional information on living objects. However, the spatial resolution of PET imaging has been limited to around 1 mm, which makes it ...

Our purpose was to assess the performance of full-dose (FD) PET image synthesis in both image and sinogram space from low-dose (LD) PET images and sinograms without sacrificing diagnostic quality ...

The field of radioligand therapy has advanced greatly in recent years, driven largely by β-emitting therapies targeting somatostatin receptor–expressing tumors and the prostate-specific membrane ...

Prostate-specific membrane antigen (PSMA) PET is a well-established imaging tool for the evaluation of primary and recurrent prostate cancer (PCa). 177 Lu PSMA-targeted radiopharmaceutical therapy ...

Nectin-4 is an overexpressed biomarker in 60%–70% of triple-negative breast cancer (TNBC) cases and an ideal target for radiotherapy and PET imaging. In this study, theranostic radioimmunoconjugates ...